Radar · Life Sciences in Quebec
Best Life Sciences Companies in Quebec, Canada
The 166 best Life Sciences companies in Quebec, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Bausch Health.
By Riya SenguptaFinancials
166companies tracked
$27.2Bdisclosed funding
0unicorns
62have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × QUEBEC
Our analysis of 50 Life Sciences companies
$27.5b in tracked funding; 76% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
76%cloud-native stacks
2025funding peak (by rounds)
2013median founding year
45median Fliar Index™
347kcombined LinkedIn audience
64%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Quebec
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Bausch Health Developer of therapeutics for the treatment of multiple diseases 67Market top 23%Funding top 27%Product top 29%Innovation top 34% All 10 signals ▾Markettop 23% Fundingtop 27% Producttop 29% Innovationtop 34% Newstop 37% Talenttop 39% Globaltop 41% Techtop 45% Fin. healthtop 49% Growthbottom 36% Market: 808 employees (top 2% of Life Sciences) · Revenue ~$8.7B Funding: Raised $25.7B across 6 rounds · 6 rounds over 11 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $25.7B | 87 mo ago | Public | 808 | Joseph Papa CEO | — | 1 internship |
| 2 | Liminal BioSciences Developer of drugs for several diseases | $307M | 67 mo ago | Public | 43 | — | — | — |
| 3 | Genizon BioSciences Genes and biomarkers discovery | $130M | 221 mo ago | Deadpooled | — | Jan Mellegers Interim President & CEO | — | — |
| 4 | Neptune Wellness Solutions Developer of proprietary bioactive ingredients for nutraceutical, medical food and pharmaceutical applications | $102M | 67 mo ago | Public | 63 | — | 19 patents Oral cannabis extract formulations and low‑temperature solvent extraction of cannabinoids | — |
| 5 | Clementia Small Molecule to treat rare bone diseases such as Fibrodysplasia Ossificans Progressiva (FOP). | $92M | 131 mo ago | Acquired | 45 | David Loew CEO | — | — |
| 6 | Endoceutics Canadian, drug discovery and development company focusing on women's health and hormone-sensitive cancer… | $85M | 113 mo ago | Funding Raised | 52 | — | — | — |
| 7 | Vivance Do Not Publish request by OD | $71M | 33 mo ago | Series B | — | Suresha Venkataraya CEO | — | — |
| 8 | Bellus Health Developer of drugs for treating rare diseases | $71M | 88 mo ago | Acquired | 13 | — | 107 patents Patents concentrated in health & consumer products | — |
| 9 | Congruence Therapeutics Developer of therapeutics for the treatment of rare diseases 50AI top 20%Funding top 24%Moat top 31%Talent top 38% All 8 signals ▾AItop 20% Fundingtop 24% Moattop 31% Talenttop 38% Marketbottom 38% Globalbottom 38% Techbottom 31% Newsbottom 22% AI: Classified as an AI company Funding: Raised $65.0M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $65M | 2 mo ago | Series B | 33 | Michael Goldsmith Co-Founder | — | — |
| 10 | Nomic Provider of next-generation proteomics platform for drug discovery and protein analysis 60Funding top 27%Growth top 28%Talent top 28%Moat top 39% All 8 signals ▾Fundingtop 27% Growthtop 28% Talenttop 28% Moattop 39% Techtop 46% Globalbottom 43% Marketbottom 39% Newsbottom 18% Funding: Raised $63.0M across 2 rounds · 2 rounds over 6 yrs (0.3/yr) Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $63M | 21 mo ago | Series B | 43 | Jeff Munzar Co-Founder & CTO | — | 1 partnership |
| 11 | Methylgene Developer of therapeutics for cancer and infectious diseases | $62M | 162 mo ago | Acquired | — | Charles Grubsztajn CEO | 412 patents Small-molecule kinase and HDAC inhibitor therapeutics for oncology | — |
| 12 | Kinova Developer of robotic arms for personal assistance and research purposes 69Patents top 20%Innovation top 27%Moat top 28%Funding top 33% All 11 signals ▾Patentstop 20% Innovationtop 27% Moattop 28% Fundingtop 33% Talenttop 34% Techtop 38% Growthtop 45% Markettop 46% Producttop 49% Globalbottom 45% Newsbottom 27% Patents: 83 patents matched (strict assignee match) · 41 filings since 2022 vs 28 in 2017-21 Innovation: 83 patents (top 12% of patent-holders) · 41 filings since 2022 vs 28 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $57M | 52 mo ago | Series B | 243 | Charles Deguire Co-Founder & CEO | 83 patents Modular robotic manipulators with protected joints, advanced admittance control, and teachable interfaces | 1 partnership |
| 13 | enGene Developer of oral non-viral gene therapy platform 50Patents top 28%Moat top 29%Funding top 30%Innovation top 38% All 9 signals ▾Patentstop 28% Moattop 29% Fundingtop 30% Innovationtop 38% Newstop 46% Growthtop 48% Marketbottom 46% Techbottom 45% Globalbottom 44% Patents: 174 patents matched (strict assignee match) · 40 filings since 2022 vs 69 in 2017-21 Moat: Editorial + unicorn rating 6/10 · IP moat: 174 patents rank vs industry peers · Fliar Intelligence Index 50/100 | $54M | 19 mo ago | Public | 57 | — | 174 patents Chitosan nanoparticle gene delivery platforms for cancer immunotherapy and localized gene expression | 1 internship · 1 award |
| 14 | Medicago Developer of vaccines to treat pandemic and seasonal influenza | $50M | 176 mo ago | Acquired | 600 | Toshifumi Tada CEO | 711 patents Plant-based virus-like particle production for influenza and other viral vaccines | — |
| 15 | KisoJi Developer of multi-specific antibodies for cancer treatment | $41M | 20 mo ago | Series B | — | David Young Co-Founder & CEO | — | — |
| 16 | Feldan Developing delivery system of proteins inside cells directly 29Funding top 33%Moat top 38%Tech bottom 46%Market bottom 38% All 5 signals ▾Fundingtop 33% Moattop 38% Techbottom 46% Marketbottom 38% Globalbottom 37% Funding: Raised $40.4M across 6 rounds · 6 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $40M | 14 mo ago | Series B | 36 | — | — | — |
| 17 | Ability Developer of modulating biotherapeutics to address cancer and autoimmune diseases | $30M | 24 mo ago | Seed | — | Jean Buerckert Co-Founder & CTO | — | 1 internship |
| 18 | Fortunafix Regenerative implants and directly reprogrammed precursor cells for brain and spinal cord injury | $25M | 103 mo ago | Deadpooled | — | Jan Ahlfors Founder & CEO | — | — |
| 19 | Thryv Therapeutics Provider of precision medicines for cardiovascular and related diseases | $24M | 36 mo ago | Series A | 22 | Paul Truex CEO | 17 patents Small-molecule SGK-1 kinase inhibitors for cancer treatment | — |
| 20 | Asmacure Specialty company developing small molecules for inflammatory lung diseases | $17M | 181 mo ago | Acqui-Hired | — | Yvon Cormier Co-Founder & CMO | — | — |
| 21 | OpSens Manufacturer of optical sensors | $15M | 60 mo ago | Acquired | 18 | Christopher Simon CEO | 140 patents Intravascular pressure sensing for cardiac/hemodynamic monitoring and structural heart interventions. | — |
| 22 | Giiant Pharma Developer of colon-specific anti-inflammatory therapy for ulcerative colitis | $12M | 59 mo ago | Seed | 4 | — | — | — |
| 23 | Ortho Regenetative Technologies Orthopedic tissue repair devices | $12M | 48 mo ago | Public | 4 | — | — | — |
| 24 | Devonian Developer of drugs for inflammatory disease and dermatology 19Funding top 38%News top 45%Growth top 48%Global bottom 25% All 5 signals ▾Fundingtop 38% Newstop 45% Growthtop 48% Globalbottom 25% Marketbottom 23% Funding: Raised $11.5M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) News: 6 BI events in 12 mo (of 71 tracked, 8 types) · -25% YoY rank vs industry peers · Fliar Intelligence Index 19/100 | $12M | 10 mo ago | Public | 7 | — | — | — |
| 25 | Reliant AI Provider of an AI platform for biopharmaceutical research and development | $11M | 21 mo ago | Acquired | — | Karl Hermann Co-Founder & CEO | — | 1 partnership |
| 26 | Immune Biosolutions Recombinant antibodies for cancer, GI diseases. | $11M | 63 mo ago | Funding Raised | 29 | — | 16 patents Therapeutic antibodies against immune receptors and bacterial/toxin antigens for disease treatment | — |
| 27 | Valence Labs AI research engine focusing on advancing drug discovery through computational biology | $8M | 54 mo ago | Acquired | 27 | Therence Bois Co-Founder & COO | — | 1 launch |
| 28 | Find Therapeutics Developer of targeted therapies modulating membrane receptors for autoimmune diseases | $8M | 21 mo ago | Series A | 8 | Philippe Douville Chief Executive Officer | — | — |
| 29 | Chlorion Pharma Canadian, early stage biotech developing small molecule therapeutics for neuropathic pain and epilepsy | $8M | 204 mo ago | Deadpooled | 11 | — | 21 patents Sulfur‑substituted heterocyclic pyrimidine/piperidine compounds for analgesic and anti‑inflammatory drugs | — |
| 30 | Acasti Developer of drug delivery technology and therapeutics for rare and orphan diseases | $7M | 32 mo ago | Series A | 33 | Pierre Lemieux Co-Founder | — | — |
| 31 | Noze Developer of a breath-based diagnostic platform to detect disease markers noninvasively | $7M | 22 mo ago | Seed | 54 | Ashok Masilamani Chief Technology Officer and Founder | — | — |
| 32 | BioIntelligence Technology Developer of intelligent monitoring instruments to enhance bioprocess development | $6M | 25 mo ago | Series A | 11 | — | — | 2 job openings |
| 33 | IntelGenx Developer of oral thin-film technologies for enhanced drug delivery | $6M | 38 mo ago | Public | 51 | — | 178 patents High‑loading oral film drug delivery systems for enhanced bioavailability | — |
| 34 | Avitia Provider of AI-powered diagnostics platform for molecular cancer testing solutions | $5M | 15 mo ago | Seed | — | James Lumsdaine Chief Executive Officer | — | — |
| 35 | Supratek Pharma Oncology drug discovery and development company | $5M | 254 mo ago | Series A | — | Oleg Romar President & CEO | 78 patents Oncology drug formulations: taxane and bendamustine delivery via novel carriers | — |
| 36 | Nutra Canada Provider of fruit, vegetable, and medicinal extracts made from organic molecules | $4M | 189 mo ago | Acqui-Hired | 17 | Andre Gosselin Founder | — | — |
| 37 | Saguaro Developer of 3D cell culture products for drug discovery | $4M | 24 mo ago | Seed | 8 | Felix Perusse Co-Founder | — | — |
| 38 | Terranueva Producer of cannabis products | $4M | 47 mo ago | Public | — | Francisco Perez Co-Founder | — | — |
| 39 | Zilia Developer of non-invasive ocular oximetry technologies | $4M | 14 mo ago | Seed | 26 | Patrick Sauvageau CEO and co-founder | 21 patents Optical spectroscopy instruments for biomedical tissue analysis and imaging | 2 partnerships |
| 40 | Optel Group Provider of Track and Trace solutions for the pharma, medical device and healthcare industries | $3M | 40 mo ago | Funding Raised | 124 | — | — | — |
| 41 | Remedium AI Provider of an AI-based platform for drug discovery | $3M | — | Seed | — | Robert Murgita Founder | — | — |
| 42 | Cryos Technologies Developing dynamic orthotics and digital postural assessment systems | $3M | 112 mo ago | Series A | 44 | John A Stimpson CEO & President | 7 patents Foot biomechanics imaging, surface analysis instrumentation, and adaptive orthotic footwear technologies. | — |
| 43 | Simmunome Provider of an AI-powered computational models for clinical trial study | $2M | 33 mo ago | Seed | 5 | Armstrong Murira Co-Founder & CEO | — | — |
| 44 | OxyNov Oxygen therapy systems | $2M | 92 mo ago | Series A | 14 | — | 8 patents Advanced respiratory gas delivery systems for patient ventilation and therapy | — |
| 45 | Advitech Research and development of nutraceuticals for immune-mediated inflammatory disorders | $1M | 190 mo ago | Deadpooled | — | Michael Stangel CEO & President | 14 patents Dairy-derived anti-inflammatory pharmaceutical formulations for treating atopic eczema | — |
| 46 | Biosyntech Biotherapeutic thermogels for tissue repair | $1M | 204 mo ago | Acquired | 45 | — | — | — |
| 47 | Clemex Technologies Digital microscopic image analysis software | $1M | 168 mo ago | Public | 37 | Yves Bassat CEO | 10 patents Automated microscope slide handling, immersion oil dispensing, and instrument calibration systems. | 3 job openings · 2 launchs |
| 48 | Starpax Biopharma Developer of therapeutics for the treatment of cancer | $782K | 16 mo ago | Seed | — | Michael Gareau Founder & CEO | 20 patents Magnetic navigation and control of therapeutic agents for targeted drug delivery | — |
| 49 | Medscint Digital radiotherapy dosimetry solutions for providers 32Talent top 38%Moat top 45%Patents top 48%Innovation top 49% All 7 signals ▾Talenttop 38% Moattop 45% Patentstop 48% Innovationtop 49% Fundingtop 49% Marketbottom 37% Globalbottom 31% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Moat: Editorial + unicorn rating 4/10 · IP moat: 3 patents rank vs industry peers · Fliar Intelligence Index 32/100 | $285K | 7 mo ago | Funding Raised | — | Simon Girard Co-Founder & CTO | 3 patents Biomedical optical imaging: spectral unmixing and Cerenkov radiation detection systems | 2 partnerships |
| 50 | Modulari-T Biosciences Developer of cell therapies for immune disorders | $125K | 36 mo ago | Seed | 5 | David White Co-Founder | — | 1 launch · 1 award |
Top 12 Life Sciences companies in Quebec
#1
Series B · Montreal, Quebec · founded 2021 · 33 employees$65Mraised▾
Series B · Montreal, Quebec · founded 2021 · 33 employees
Developer of therapeutics for the treatment of rare diseases. It offers an in-silico platform that enables the design of small molecules that stabilizes misfolded proteins to treat rare diseases. It offers computational drug discovery engine called Revenir which captures the biophysical changes caused by mutations in proteins. It examines surface features and numerous biophysical descriptors of both the mutated and wild-type proteins. It offers a lead candidate CGX-926 for obesity.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
AI
top 20%Funding
top 24%Moat
top 31%Talent
top 38%Market
bottom 38%Global
bottom 38%AI: Classified as an AI company
Funding: Raised $65.0M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) · Last round Series B (Mar 2026)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Senior Scientist in Computational Chemistry
Activity (LinkedIn): 1 partnerships (incl. ONO PHARMACEUTICAL CO., LTD.) announced in 12 mo
Funding rounds
- Mar 2026Series B$39.5M
- Sep 2025Series B$32M
- Mar 2023Series A$15M
- Feb 2022Series A$50M
Founders & team
Investors
Amplitude, Fonds de solidarite FTQ, Lumira Ventures, Invest Quebec, Orbimed, Driehaus
Tech stack
BootstrapCore-JsGodaddyGoogle Font ApiGsapIsotope
#2
Series B · Quebec City, Quebec · founded 2007 · 36 employees$40.4Mraised▾
Series B · Quebec City, Quebec · founded 2007 · 36 employees
Feldan is developing regenerative medicine therapeutic applications based on Feldan’s proprietary technology. The company has developed Feldan Shuttle, a protein-based technology platform that directly delivers proteins – such as nucleases or transcription factors - inside cells to specific cellular compartments. The Shuttle can overcome obstacles faced by nucleic acid delivery for therapeutic use by decreasing the regulatory process and accelerating the translation of discoveries into clinical applications. The Shuttle also allows enables the development of in-house medical applications as well as in collaboration with partners.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 33%Moat
top 38%Tech
bottom 46%Market
bottom 38%Global
bottom 37%Funding: Raised $40.4M across 6 rounds · 6 rounds over 11 yrs (0.5/yr) · Last round Series B (Apr 2025)
Moat: Editorial + unicorn rating 4/10 · Soonicorn
Tech: 20 technologies across 3/8 capability areas · Cloud: Cloudflare · Security: Cloudflare Bot Management, Hsts
Funding rounds
- Apr 2025Series B—
- Feb 2025Series B—
- Sep 2024Series B$21M
- Jun 2023Series B$16.5M
Investors
Genesys Capital, Fonds de solidarite FTQ, Anges Quebec, FIER Succes, Invest Quebec, Amgen
Tech stack
AosCdnjsCloudflareCloudflare Bot ManagementCore-JsFont Awesome
#3
Public · Quebec City, Quebec · founded 2013 · 7 employees$11.5Mraised▾
Public · Quebec City, Quebec · founded 2013 · 7 employees
Developer of drugs for inflammatory diseases and dermatology. The flagship product, Thykamine, has shown anti-inflammatory and anti-oxidant properties, as per company claims, and is currently under development for the treatment of ulcerative colitis, atopic dermatitis, eczema, and psoriasis. The company also develops cosmetic products which include anti-aging products, and sun care products for women and men.
Fliar Intelligence Index™ 19how this company ranks against its industry peers
Funding
top 38%News
top 45%Growth
top 48%Global
bottom 25%Market
bottom 23%Funding: Raised $11.5M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) · Last round Post IPO (Aug 2025)
News: 6 BI events in 12 mo (of 71 tracked, 8 types) · -25% YoY · Top themes: Earnings, Announcements
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 350 LinkedIn followers
Funding rounds
- Aug 2025Post IPO$1.7M
- Mar 2024Post IPO$166K
- May 2023Post IPO$889.6K
- Nov 2021Post IPO$2.3M
#4
Public · Saint laurent, Quebec · founded 1999 · 57 employees$54Mraised▾
Public · Saint laurent, Quebec · founded 1999 · 57 employees
EnGene is developing a non-viral gene therapy platform for the delivery of nucleic acid payloads to mucosal tissues. Its flagship platform DDX is a derived chitosan platform delivers DNA and various forms of RNA to broad tissue and disease applications. It has also developed a gut-optimized gene delivery formulation, Gene Pill for Short Bowel Syndrome (SBS). Gene Pill enables the oral delivery of DNA encoding a long-acting GLP-2 analog directly to GIT.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Patents
top 28%Moat
top 29%Funding
top 30%Innovation
top 38%News
top 46%Growth
top 48%Patents: 174 patents matched (strict assignee match) · 40 filings since 2022 vs 69 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 6/10 · IP moat: 174 patents · 10 curated direct competitors tracked
Funding: Raised $54.0M across 7 rounds · 7 rounds over 25 yrs (0.3/yr) · Last round Post IPO (Oct 2024)
Audience (LinkedIn): 18k LinkedIn followers — 5.3% of this cohort's audience
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- Oct 2024Post IPO$43.4M
- Feb 2024Post IPO—
- Dec 2023Convertible Debt$22.5M
- Oct 2020Grant (prize money)—
Investors
Forbion, Fonds de solidarite FTQ, Lumira Ventures, Inbio Ventures, National Research Council Canada, Saad Investments
Tech stack
Anime.JsApple Icloud MailCloudflareCookieyesCore-JsGoogle Font Api
#5
Public · Laval, Quebec · founded 1960 · 808 employees$25.7Braised▾
Public · Laval, Quebec · founded 1960 · 808 employees
Developer of therapeutics for the treatment of multiple diseases. The company manufactures pharmaceutical products in the areas of dermatology, gastrointestinal disorders, eye health, neurology, and more. The lead candidate of the company IDP-120 is used to treat acne. In 2023, the company recorded annual revenues of $8.15B and a net loss of $0.36B.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Market
top 23%Funding
top 27%Product
top 29%Innovation
top 34%News
top 37%Talent
top 39%Market: 808 employees (top 2% of Life Sciences) · Revenue ~$8.7B · Top-5,000,000 web property
Funding: Raised $25.7B across 6 rounds · 6 rounds over 11 yrs (0.5/yr) · Last round Conventional Debt (Mar 2019)
Product: 0 product launch events in 12 mo · 8 distinct product lines · Company stage: Public
Audience (LinkedIn): 140k LinkedIn followers — 40.2% of this cohort's audience
Funding rounds
- Mar 2019Conventional Debt$500M
- Nov 2018Conventional Debt$1.5B
- Jun 2018Conventional Debt$5.8B
- Jun 2018Conventional Debt—
Founders & team
Investors
ValueAct Capital, CapTrust, Citizens Bank, Steward Partners Global Advisory, Stonebridge Capital Advisors, Icahn Enterprises L P
Tech stack
Amazon AlbAmazon Web ServicesApache Http ServerAzureAzure MonitorBootstrap
#6
Series B · Montreal, Quebec · founded 2017 · 43 employees$63Mraised▾
Series B · Montreal, Quebec · founded 2017 · 43 employees
Provider of next-generation proteomics platform for drug discovery and protein analysis. The company has developed the nELISA, a next-generation ELISA platform by using DNA nanotechnology for measuring proteins and applicable for a wide variety of use cases within drug and biomarker development workflows.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 27%Growth
top 28%Talent
top 28%Moat
top 39%Tech
top 46%Global
bottom 43%Funding: Raised $63.0M across 2 rounds · 2 rounds over 6 yrs (0.3/yr) · Last round Series B (Sep 2024)
Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 11k LinkedIn followers — 3.2% of this cohort's audience
Activity (LinkedIn): 1 partnerships (incl. Health and Environmental Sciences Institute (HESI) Global OASIS Consortium) announced in 12 mo
Funding rounds
- Sep 2024Series B$42M
- Dec 2021Series A$17M
- 2020Seed—
Founders & team
Investors
Amplitude, AVANT BIO, Lux Capital, Real Ventures, SR One, 2048 Ventures
Tech stack
Amazon Web ServicesCloudflareCloudflare Bot ManagementCore-JsGoogle AnalyticsGoogle Font Api
#7
Series B · Montreal, Quebec · founded 2009$41.3Mraised▾
Series B · Montreal, Quebec · founded 2009
Developer of multi-specific antibodies for cancer treatment. It offers tri-specific immuno-oncology antibody candidates which include KJ-101 for neuroendocrine solid tumors, KJ-102 for acute myeloid leukemia, and KJ-103 for TROP-2 Expressing solid tumors.
Funding rounds
- Oct 2024Series B$40.6M
- Jun 2018Series A—
- Oct 2016Seed$751.9K
Founders & team
Investors
Invest Quebec, Lumira Ventures, Fonds de solidarite FTQ, adMare BioInnovations, Remiges Ventures, BDC
#8
Seed · Quebec City, Quebec · founded 2018 · 26 employees$4Mraised▾
Seed · Quebec City, Quebec · founded 2018 · 26 employees
Developer of non-invasive ocular oximetry technologies. The company offers its propriety technology for the early detection of ocular disease. The company offers full light spectrum technology to measure the oxygen in ocular and to measure the biomarker in the eye and information on the metabolic state of the eye.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers
Activity: 2 partnerships (incl. Instruments Ophtalmiques INNOVA) announced in 12 mo
Funding rounds
- Apr 2025Seed$984.7K
- Aug 2021Seed$4M
Founders & team
Investors
Anges Quebec
Tech stack
CdnjsCloudflareCloudflare Bot ManagementCloudflare Browser InsightsDiviGoogle Analytics
#9
Seed · Montreal, Quebec · founded 2025$5Mraised▾
Seed · Montreal, Quebec · founded 2025
Provider of AI-powered diagnostics platform for molecular cancer testing solutions. The platform delivers actionable insights, real-time genomic data access, and clinical insights to assist treatment decision-making. It offers ready-to-use NGS-based tissue and liquid biopsy panels that integrate into existing workflows. The platform also identifies personalized treatment options and connects to localized clinical trials.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 8k LinkedIn followers — 2.3% of this cohort's audience
Funding rounds
- Feb 2025Seed$5M
Founders & team
Investors
PacBridge Partners
#10
Funding Raised · Quebec City, Quebec · founded 2018$284.7Kraised▾
Funding Raised · Quebec City, Quebec · founded 2018
Digital radiotherapy dosimetry solutions for providers. The company has developed dosimetry measurement tools like 'HS-RP200' and 'HYPERSCINT' for medical physicists. It has features for real-time dosimetry, a portable modular platform, customized probes, and more.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Talent
top 38%Moat
top 45%Patents
top 48%Innovation
top 49%Funding
top 49%Market
bottom 37%Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 4/10 · IP moat: 3 patents
Patents: 3 patents matched (strict assignee match) · 3 filings since 2022 vs 0 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 3k LinkedIn followers
Activity (LinkedIn): 2 partnerships (incl. S.I.T. Sordina IORT Technologies S.p.A.) announced in 12 mo
Funding rounds
- Nov 2025Conventional Debt$284.7K
Founders & team
Investors
Government of Canada
#11
Acquired · Montreal, Quebec · founded 2023$11.3Mraised▾
Acquired · Montreal, Quebec · founded 2023
Provider of an AI platform for biopharmaceutical research and development. It offers a flagship product, Reliant Tabular that streamline the process of finding scientific evidence for decision-making, reducing data processing time. It combines an AI engine with customized tools to assist with portfolio strategy and launch success prediction. The platform automates data ingestion and extraction, and provides knowledge graphs to map relationships between trials and mechanisms.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 7k LinkedIn followers — 2.0% of this cohort's audience
Activity: 1 partnerships (incl. Cohere) announced in 12 mo
Funding rounds
- Aug 2024Seed$11.3M
Founders & team
Investors
Tola Capital, Inovia Capital
#12
Series A · Saint laurent, Quebec · founded 2017 · 8 employees$8.1Mraised▾
Series A · Saint laurent, Quebec · founded 2017 · 8 employees
Developer of targeted therapies modulating membrane receptors for autoimmune diseases. It designs therapies through precision-targeting of key receptors. The company's development programs focus on treating inflammatory autoimmune conditions. It utilizes innovative chemistry to design modulators. The company has a multidisciplinary team focused on drug development. It has a clinical advisory board and a scientific advisory board.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 1k LinkedIn followers
Funding rounds
- Sep 2024Series A$8.1M
- Jun 2020Seed—
Founders & team
Investors
Invest Quebec, CTI Life Sciences Fund, adMare BioInnovations, Domain Therapeutics, PeptiMimesis
Funding & investor landscape
$27.2Btotal disclosed funding
55companies funded
155disclosed rounds
1rounds last 90 days
Most active investors
Notable founders
Michael Goldsmith
Co-Founder · Congruence Therapeutics
Clarissa Desjardins
Co-Founder & CEO · Congruence Therapeutics
Joseph Papa
CEO · Bausch Health
Jeff Munzar
Co-Founder & CTO · Nomic
Arya Tavakoli
Co-Founder & Head of Laboratory Operations · Nomic
David Young
Co-Founder & CEO · KisoJi
Patrick Sauvageau
CEO and co-founder · Zilia
Dominic Sauvageau
Co-Founder · Zilia
James Lumsdaine
Chief Executive Officer · Avitia
Simon Girard
Co-Founder & CTO · Medscint
Francois Proulx
Co-Founder & CEO · Medscint
Karl Hermann
Co-Founder & CEO · Reliant AI
Prism market signals · Canada · country-scoped Prism corpus, 188,258 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · Canada
How research on Biotechnology is moving in Canada
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 990 Canada-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 39% → 44% across 2008–2026.
top research entities
- Ministry of Agriculture118
- Ministry of Education70
- University of Toronto61
- McGill University60
- Agriculture and Agri-Food Canada58
leading researchers
Davoud Torkamaneh · Maxime de Ronne · Vincent Lefebvre · Sylvie Deslauriers · Théo Devèze · Bernard R. Glick · Rotimi E. Aluko · Warren C. W. Chan
▲
Breakthroughs267 · 27%
▼ 31%→27% share
▼0.9× share momentum0 median citations82% since 2021mostly empirical
Gene-editing research is surging — Canadian biotech breakthrough papers on Gene rose from 3 to 32, alongside newly emerging Antibody (12) and Immune system (8) topics.
rising sub-themes (early→recent)
- Gene3→32
- Mutant2→13
- Genome2→12
- Transcription factor2→11
- Transcription (linguistics)1→9
Newly emergingAntibody 0→12 · Immune system 0→8 · Mutation 0→7
Landmark In situ click chemistry generation of cyclooxygenase-2 inhibitors · 7,514 cites
◆
Advancements374 · 38%
▲ 31%→40% share
▲1.3× share momentum0 median citations86% since 2021mostly empirical
Microbiome and Transcriptome research newly emerged at 15 papers each as Advancements field-share climbed from 31% to 40%.
rising sub-themes (early→recent)
- Gene2→40
- Fermentation1→12
- Antimicrobial1→9
- Population1→9
- Agriculture1→8
Newly emergingMicrobiome 0→15 · Transcriptome 0→15 · Metagenomics 0→10
Landmark Lignin Valorization: Improving Lignin Processing in the Biorefinery · 3,958 cites
▼
Concerns164 · 17%
▼ 22%→14% share
▼0.6× share momentum0 median citations71% since 2021mostly reviews
Antibiotic resistance and Agriculture concerns are intensifying — both rose from 3 to 10 papers as Concerns field-share fell from 22% to 14%.
rising sub-themes (early→recent)
- Agriculture3→10
- Antibiotic resistance3→10
- Antimicrobial1→6
- Human health2→7
- Microbiome2→6
Newly emergingContext (archaeology) 0→8 · Resistance (ecology) 0→6 · Gene 0→6
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · Canada
Where biotechnology is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Montreal99 · +0.45
Edmonton/Calgary71 · +0.39
Toronto63 · +0.49
Vancouver61 · +0.40
Ottawa/Kingston34 · +0.40
Waterloo/Hamilton31 · +0.41
PATENT SIGNAL · Canada
Who's filing biotechnology patents in Canada
Canada biotechnology patent filing is accelerating — 18,553 filings from 8,000 assignees (2016–2025), led by UNIV British Columbia, UNIV Health Network, NAT RES Council Canada; annual filings 1716→1734.
18,553 filings8,000 assigneespeak 2082/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- UNIV British Columbia1570
- UNIV Health Network1208
- NAT RES Council Canada900
- UNIV Alberta753
- CA NAT Research Council699
- Medicago680
- UNIV Saskatchewan597
- Zymeworks594
Common questions
How many Life Sciences companies are there in Quebec, Canada?
Radar tracks 166 indexable Life Sciences companies headquartered in Quebec, Canada that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Quebec, Canada?
The Life Sciences companies in Quebec, Canada on this list have raised a combined $27.2B in disclosed equity funding across 55 funded companies.
Which is the highest-funded Life Sciences company in Quebec, Canada?
Bausch Health is the highest-funded Life Sciences company in Quebec, Canada, with $25.7B in disclosed equity funding.
How many Life Sciences companies in Quebec, Canada are funded?
55 of the 166 Life Sciences companies in Quebec, Canada on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Quebec, Canada?
None of the Life Sciences companies in Quebec, Canada on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Quebec, Canada Life Sciences companies?
The most active investors in Quebec, Canada Life Sciences companies on this list include Fonds de solidarite FTQ, Invest Quebec, ACET, Amplitude, BDC.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.